LakeShore Biopharma Appoints New Independent Director
Ticker: LSBWF · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance, board-appointment
TL;DR
LAKESHORE BIOPHARMA ADDS NEW INDEPENDENT DIRECTOR, JIANJUN LIU, TO BOARD.
AI Summary
LakeShore Biopharma Co., Ltd. announced the appointment of Mr. Jianjun Liu as an independent director and a member of the audit committee, effective September 10, 2025. Mr. Liu brings extensive financial and auditing experience to the board. This appointment follows the company's name change from YS Biopharma Co., Ltd. on March 10, 2023.
Why It Matters
The addition of an independent director with financial expertise can enhance corporate governance and investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a board appointment and does not involve significant financial transactions or operational changes.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- Jianjun Liu (person) — Appointed Independent Director
- YS Biopharma Co., Ltd. (company) — Former Company Name
- March 10, 2023 (date) — Date of Name Change
- September 10, 2025 (date) — Effective Date of Appointment
FAQ
Who is Jianjun Liu and what is his background?
The filing states Jianjun Liu has been appointed as an independent director and member of the audit committee. His specific background is not detailed in this excerpt, but the context implies financial and auditing experience.
When was the appointment effective?
The appointment of Jianjun Liu was effective September 10, 2025.
What is LakeShore Biopharma's previous name?
LakeShore Biopharma Co., Ltd. was formerly known as YS Biopharma Co., Ltd. (and YishengBio Co., Ltd.).
What is the company's primary business?
The company is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is LakeShore Biopharma's principal executive office located?
The company's principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Filing Stats: 179 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-09-10 08:58:55
Filing Documents
- ea0256799-6k_lakeshore.htm (6-K) — 11KB
- ea025679901ex99-1_lakeshore.htm (EX-99.1) — 7KB
- 0001213900-25-086391.txt ( ) — 20KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release - LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 10, 2025 2